Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Francesca Guijarro, Marc Dabad, Mònica López-Guerra, Alex Bataller Torralba, Sandra Castaño-Díez, Carlos Jimenez-Vicente, Marta Garrote, José Ramón Álamo Moreno, Marta Pratcorona, Neus Villamor, Dolors Colomer, Silvia Bea, Dolors Costa, Anna Esteve-Codina, Marina Díaz-Beyá, Jordi Esteve

Blood (2023) 142 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2023-188261

Published: 2023

Journal Articles

Whole Genome Sequencing of B-Cell Neoplasms with t(14;19)(q32;q13) Reveals Different Entities

Blood (2021) 138 (Supplement 1): 3709.

https://doi.org/10.1182/blood-2021-150891

Published: 2021

Journal Articles

Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes

Blood (2020) 136 (12): 1419–1432.

https://doi.org/10.1182/blood.2020005289

Published: 2020

Includes: Supplemental data

Journal Articles

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Blood (2019) 134 (Supplement_1): 4015.

https://doi.org/10.1182/blood-2019-127199

Published: 2019

Journal Articles

Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

Blood (2019) 134 (Supplement_1): 4287.

https://doi.org/10.1182/blood-2019-126557

Published: 2019

Journal Articles

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 − mantle cell lymphoma

Blood (2019) 133 (9): 940–951.

https://doi.org/10.1182/blood-2018-07-862151

Published: 2019

Includes: Supplemental data

Journal Articles

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Andrea Kuendgen, MD, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, Alan F. List, MD, Mario Cazzola, Amy E. DeZern, MD, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A. Van de Loosdrecht, MD PhD, Hartmut Döhner, MD, Xavier Calvo, MD, Sabine Blum, Arturo Pereira, MD PhD, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, MD, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria López-Pavía, Claudia D. Baldus, MD, Montserra Martinez-de-Sola, Reinhard Stauder, MD MSc, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, MD PhD, Benet Nomdedeu, Francesc Cobo, Francesc Sole, PhD, Rainer Haas, MD, Ulrich Germing, MD, Peter L Greenberg, MD, Detlef Haase, MD PhD, Guillermo Sanz

Blood (2018) 132 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2018-99-118215

Published: 2018

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes

Blood (2016) 128 (22): 4331.

https://doi.org/10.1182/blood.V128.22.4331.4331

Published: 2016

Journal Articles

Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)

Blood (2015) 126 (23): 1672.

https://doi.org/10.1182/blood.V126.23.1672.1672

Published: 2015

Journal Articles

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, Amy E. DeZern, MD MHS, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A van de Loosdrecht, MD PhD, Arjan A van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, Sabine Blum, Arturo Pereira, Peter Valent, MD, Dolors Costa, Aristoteles Giagounidis, MD PhD, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, Maria Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, Detlef Haase, MD, Ana Africa Martin, Claudia D Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD MSc, Brayan Merchan, MD, Claudia Mende, María Teresa Ardanaz, MD, Christina Ganster, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Nomdedeu Benet, Peter L. Greenberg, MD, Ulrich Germing, MD, Guillermo Sanz, MD PhD

Blood (2015) 126 (23): 609.

https://doi.org/10.1182/blood.V126.23.609.609

Published: 2015

Journal Articles

Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model

Xavier Calvo, MD, Meritxell Nomdedeu, MD PhD, Rodrigo Santacruz, MD, Núria Martínez, MD, Dolors Costa, PhD, Arturo Pereira, MD PhD, Natalia Estrada, Blanca Xicoy, MD PhD, Jordi Esteve, MD PhD, Benet Nomdedeu, MD PhD

Blood (2014) 124 (21): 4660.

https://doi.org/10.1182/blood.V124.21.4660.4660

Published: 2014

Journal Articles

Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome

Meritxell Nomdedeu, MD PhD, Xavier Calvo, MD, Arturo Pereira, MD PhD, Dolors Costa, PhD, Carmen Pedro, MD, Maria Teresa Cedena, MD, María López-Pavía, MD, Ana Africa Martín, MD, Montserrat Martínez de Sola, MD, Brayan Marcel Merchan, MD, Maria Teresa Ardanaz, MD, Jordi Esteve, MD PhD, Francesc Cobo, MD PhD, Guillermo F. Sanz, MD PhD, Benet Nomdedeu, MD PhD

Blood (2014) 124 (21): 4636.

https://doi.org/10.1182/blood.V124.21.4636.4636

Published: 2014

Journal Articles

Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma

Meritxell Nomdedeu, MD, PhD, Marta Pratcorona, MD, Marina Díaz-Beyá, MD, Xavier Calvo, MD, Mari Carmen Lara-Castillo, PhD, Daniel Esteban, MD, Maria Rozman, MD, PhD, Dolors Costa, PhD, Jordi Esteve, MD, PhD, Ruth M. Risueño, PhD

Blood (2013) 122 (21): 1422.

https://doi.org/10.1182/blood.V122.21.1422.1422

Published: 2013

Journal Articles

Evaluation Of Two Prognostic Scoring Systems For Chronic Myelomonocytic Leukemia (CMML): CMML-Specific Prognostic Scoring System (CPSS) and MD Anderson Prognostic Score (MDAPS) In A Series Of 122 Cases Of De Novo CMML

Xavier Calvo, MD, Meritxell Nomdedeu, MD, PhD, Dolors Costa, PhD, Arturo Pereira, MD, PhD, Núria Martínez, Jordi Esteve, MD, PhD, Blanca Xicoy, MD, PhD, Benet Nomdedeu, MD, PhD

Blood (2013) 122 (21): 2810.

https://doi.org/10.1182/blood.V122.21.2810.2810

Published: 2013

Journal Articles

Detailed Molecular Analysis of Patients with Chronic Lymphocytic Leukemia Carrying 17p Deletions Reveals Concurrent Abnormalities with Prognostic Impact

Julio Delgado, Itziar Salaverría, Eriong Lee, Laura Jiménez, Alba Navarro, Dolors Colomer, Ivan Dlouhy, Laura Conde, Alejandra Martinez-Trillos, Cristina Lopez, Neus Villamor, MD, PhD, Marta Aymerich, MD, PhD, María Rozman, Eva Giné, Dolors Costa, Anna Carrió, Armando López-Guillermo, Elías Campo, Sílvia Beà

Blood (2012) 120 (21): 4577.

https://doi.org/10.1182/blood.V120.21.4577.4577

Published: 2012

Journal Articles

Prognostic Performance of the Cytogenetic Risk Classification Defined by the German-Austrian Myelodysplastic Syndromes (MDS) Study Group and Its Contribution to the International Prognostic Scoring System (IPSS) and the World Health Organization-Based Prognostic Scoring System (WPSS)

Benet Nomdedeu, MD, Meritxell Nomdedeu, MD, Arturo Pereira, MD, Dolors Costa, MD, Anna Carrió, MD, Xavier Calvo, MD, Mohamed Belkaid, Francesc Cobo, MD, Alvaro Urbano-Ispizua, MD

Blood (2010) 116 (21): 4005.

https://doi.org/10.1182/blood.V116.21.4005.4005

Published: 2010

Journal Articles

Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.

Rita Coutinho, MD, Dolors Costa, PhD, Ana Carrió, PhD, Ana Vidal, BS, Mohammed Belkaid, MS, Elias Campo, MD, PhD, Emili Montserrat, MD, PhD, Benet Nomdedeu, MD

Blood (2009) 114 (22): 1746.

https://doi.org/10.1182/blood.V114.22.1746.1746

Published: 2009

Journal Articles

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).

Marta Pratcorona, Montserrat Torrebadell, Neus Villamor, Maria Rozman, Mireia Camós, Ana Carrió, Dolors Costa, Marina Díaz Beyáa, Emili Montserrat, Jordi Esteve

Blood (2009) 114 (22): 2611.

https://doi.org/10.1182/blood.V114.22.2611.2611

Published: 2009

Journal Articles

Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group.

Blood (2009) 114 (22): 1003.

https://doi.org/10.1182/blood.V114.22.1003.1003

Published: 2009

NARROW

Clinical Characterization of Fusion Genes in Acute Myeloid Leukemia without Recurrent Genetic Abnormalities

Whole Genome Sequencing of B-Cell Neoplasms with t(14;19)(q32;q13) Reveals Different Entities

Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes

Splenic Marginal Zone Lymphoma: Risk of Transformation, Clinico-Biological Features at Transformation and Prognosis

Chromosome Banding Analysis Versus Genomic Microarrays: A Comparison of Methods for Genomic Complexity Risk Stratification in Chronic Lymphocytic Leukemia Patients with Complex Karyotype

CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1 − mantle cell lymphoma

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes

Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD)

An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model

Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome

Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma

Evaluation Of Two Prognostic Scoring Systems For Chronic Myelomonocytic Leukemia (CMML): CMML-Specific Prognostic Scoring System (CPSS) and MD Anderson Prognostic Score (MDAPS) In A Series Of 122 Cases Of De Novo CMML

Detailed Molecular Analysis of Patients with Chronic Lymphocytic Leukemia Carrying 17p Deletions Reveals Concurrent Abnormalities with Prognostic Impact

Prognostic Performance of the Cytogenetic Risk Classification Defined by the German-Austrian Myelodysplastic Syndromes (MDS) Study Group and Its Contribution to the International Prognostic Scoring System (IPSS) and the World Health Organization-Based Prognostic Scoring System (WPSS)

Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.

Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).

Prognostic Value of Monosomal Karyotype in Patients with Primary Acute Myeloid Leukemia On Behalf of Spanish CETLAM Group.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only